China PharmaHub Announces Incorporation of CPC NuLife, Inc.

BOSTON, Jan. 25, 2011 /PRNewswire/ -- China PharmaHub Corp. (OTC Bulletin Board Symbol: CPHB), a biopharmaceutical acquisition and development company, today announced the formation of CPC NuLife, Inc., a subsidiary company. CPC NuLife, Inc. will focus on the commercialization of CPC001, an irradiated microsphere device used for the treatment of liver cancer pursuant to an exclusive distribution agreement mentioned below. The company also will engage in research and development efforts for next generation products and additional indications.

(Logo: http://photos.prnewswire.com/prnh/20100907/LA60053LOGO)

"We continue to execute on our corporate strategy, leveraging our advisory boards and our networks and agreements in China to create focused, project-specific subsidiaries to develop and commercialize our in-licensed assets," said Richard Lui, CEO of China PharmaHub. "We are very excited by the opportunity to bring this important treatment for liver cancer to China and Southeast Asia. Approximately three-quarters of liver cancer cases worldwide occur in this region, which we believe would greatly benefit from the introduction of this cost-effective, outpatient therapy."

China PharmaHub will help form a management team to lead the new organization and will assist with applications for regulatory approval of CPC001 in China and Southeast Asia. The company plans to submit registration documents to China's State Food and Drug Administration (SFDA) in 2012 for the marketing and sale of the device, and upon SFDA clearance, plans to submit registration documents in the remaining countries where it has exclusive rights. A market feasibility study has already been completed in these countries.

In August 2010, China PharmaHub signed an Exclusive Distribution Agreement for the microsphere device with a global leader in precision glass technology. Under the terms of the agreement, PharmaHub has the exclusive rights to market the microsphere device in China, Hong Kong, Taiwan, and Macau (the "Greater China Region") as well as Singapore, Malaysia, and Bangladesh.

About China PharmaHub Corp.

China PharmaHub Corp. is a development stage company engaged in the business of licensing, developing and commercializing innovative products for a wide variety of human diseases from biopharmaceutical companies based in the United States and/or China. PharmaHub brings a unique blend of relationships and resources to assist scientists and companies to develop, commercialize, market and sell pharmaceutical, biotechnology and related technologies, as well as offer improved, cost-effective alternatives to current methods of treatment or enable the discovery, research and development of new medicines. PharmaHub's corporate headquarters are located in Los Angeles and Boston. More information on China PharmaHub is available at www.chnpharmahub.com.

Forward-Looking Statements

This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Except as otherwise required by the federal securities laws, the Company disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein.

SOURCE China PharmaHub Corp.